Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -21.00 -8.68% 221.00 92,994 12:58:52
Bid Price Offer Price High Price Low Price Open Price
220.00 223.00 236.50 220.00 236.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.75 -138.78 -13.17 1,910
Last Trade Time Trade Type Trade Size Trade Price Currency
13:16:52 O 274 220.63 GBX

Hutchmed (china) (HCM) Latest News

More Hutchmed (china) News
Hutchmed (china) Investors    Hutchmed (china) Takeover Rumours

Hutchmed (china) (HCM) Discussions and Chat

Hutchmed (china) (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchmed (china) trades in real-time

Hutchmed (china) (HCM) Top Chat Posts

Hutchmed (china) Daily Update: Hutchmed (china) Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 242p.
Hutchmed (china) Limited has a 4 week average price of 149.60p and a 12 week average price of 137.80p.
The 1 year high share price is 633p while the 1 year low share price is currently 137.80p.
There are currently 864,460,700 shares in issue and the average daily traded volume is 79,429 shares. The market capitalisation of Hutchmed (china) Limited is £1,910,458,147.
donald pond: Yes, I've been out of HCM for years, but it does seem that the FDA is increasingly politicised and I doubt a US company with this treatment would have had the same result. Good luck holders, always had a soft spot for HCM but sad to see CH go.
nerdofsteel: correction! 7 years of share price growth/mcap wiped out despite the huge change in the pipeline, and 3 drugs on the market.
nerdofsteel: 6.5 years of share price growth wiped out, and all that time ago revs were $91m, last year they were $342m, this year they will be around $516m. Losses have widened but the current mcap makes no sense.
nerdofsteel: Given my average buy price is around 250p I won't be selling either, I was planning on selling my entire holding when the company starts generating cash in 2025/6 when I predicted a share price of around £10-£12 but that is looking unrealistic now.
1jat: Lomcovaks The benefit of ADS are better liquidity and narrower spreads….however if you follow the HK, UK and US prices you will see that the UK has large spreads when the US market is closed. Annual ISA volumes are unlikely to be a problem for UK markets, unless you are going to invest many years of investments. I have added 1-2000 shares each ISA season using the UK market. I would generally only trade the UK a shares between 3pm-4pm when the share price usually matches the US price. If there is a large fall in the US, and you think it could reverse, then this is the time to buy the UK market with the US closed as UK market makers tend to be risk averse and will continue to sell to us at yesterday’s US price. HK generally trades a couple of % higher than the US, i am not sure why but it is possibly lower taxes. II will also allow you to deal the HK shares….same exchange rate issues apply. Hope that is of assistance.
1jat: The FDA recently knocked back Innovent and Lilly application for Tyvyt that was based on China data only. It seems they made the application without consulting the FDA. HCM have taken a different approach with surufatinib performing the necessary bridging study after consulting the FDA…..hopefully this puts HCM in a much better position….they also consulted EMA and can use the same China and US dataset for Europe. Japan needs its own study which is in progress. HCM is cautious and appears to have developed decent relations with key regulators. this reduces the risk of regulatory rejection at the expense of slower progress….I think slow and steady wins the race in this case. Not long to go…I expect HCM will get approval, but I would not be surprised if the US gave conditional approval with a confirmatory study required. A complete response letter (rejection) would not appear to be consistent with the process followed to date with close communication with FDA about the route to approval.
steeplejack: It could be that General Atlantic’s option to buy further stock at $30 has possibly already expired ie 18 months from the original purchase but i could be wrong.Is that 18 ‘calendar̵7; months and from which date does the 18 month term commence.Is it from July 6th 2020 ie GA stated of its original purchase of stock that ,”the expected effective date of admission of these securities to AIM is on July 6, 2020”.It’;s difficult to discern but GA must of been tempted to exercise that warrant many times over the last 18 months being as mesmorized like the rest of us by the unfathomable volatilty of the stock price.I’d be surprised if they were to exercise the option at the eleventh hour but arguably a stronger share price would have made an exercise of the warrant very tempting if only to “flip” them as suggested in the earlier post by 1jat.HMED hasn’t aided its cause by a fairly cavalier approach to fund raising over the years but nonetheless the lacklustre share price is disappointing.Last August Jeffries issued a buy note with a target price of $52 to no avail.It is only due to a deep rooted suspicion that if i sell my core holding the shares will inevitably shoot higher,that keeps me hanging on here! LONDON, June 25, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med̶1; or the “Company”;) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the sale of US$100 million of shares at a price equivalent to US$25.00 per American Depositary Share (“ADS”) via a private placement to General Atlantic, a leading global growth equity firm. This fundraise could increase to US$200 million, through a warrant granted with a term of 18 months for a further US$100 million in Chi-Med shares exercisable at a price per share equivalent to US$30.00 per ADS, a 32.5% premium to the 30-day VWAP.
1jat: general Atlantic has two days to exercise its second 100m USD investment. It is important as a sign of confidence among existing investors. If they don’t invest it looks bad for the future and the share price will fall to less than ADS 30USD equivalent If they try to flip the new investment that will have a similar effect, so they would need to hold for a while… With the share price well above the option price they should invest…as long as they have funding available.
sportii: 13.5 million shares traded with in the first two hours of trading! Clearly a sign of interest among Asian investors. SP at 56.3 HKD which makes AIM listed HCM share price £5.20 (approximately). Company website yet to show price.
sportii: Not sure the company gives any importance to investors’ interests. Its glaringly true that the market valuation is very very low. Is there another pharma company of this magnitude with such low market valuation? Over the last 5/6 years, on 4-5 occasions, the share price climbed up on a steady pace, backed up by genuinely solid reasons(successful clinical trials, extending operational activities to the USA, enviable pipeline, triple hundred millions of investments by two major funds, drugs getting approved by authorities and subsequent marketing etc., etc.). However, on every occasion, share price failed to maintain the higher valuation longer than few weeks due to various (some times without any) reasons. For example, 6-8 weeks ago, AIM share price was > £5.30 and NYSE ADRs > $37. One fine day, following the announcement of reasonably satisfactory annual results, more than a million ADRs got traded (?sold) which caused severe drop in the share price Surprisingly, the very following day, a million ADRs got (?)bought, with no improvement in the sp! Presently, share price is languishing at £4 (and ADRs $27). The company keeps the news of Asian listing in the circulation as a hope for the investors. Is it a carrot hanging at a distance? Personally, I feel appreciating Hutchmed for the great work of research and development of newer therapies for oncology and immunology which, undoubtedly, will be useful to millions of people. But, as an investor I remain seriously sceptical about poor show in improving market valuation. (PS: no intention of recommending either to buy or sell. Do your own research)
Hutchmed (china) share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220705 12:44:18